Gene therapy for restenosis current status

Drugs

Volumn 62, Issue 11, 2002, Pages 1575-1585

  Rutanen, Juha ^a   Markkanen, Johanna ^a   Ylä Herttuala, Seppo ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; BETA INTERFERON; BINDING PROTEIN; CYCLINE; CYTOKINE; CYTOSINE DEAMINASE; DNA; GROWTH FACTOR; HOMEODOMAIN PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KALLIKREIN; NATRIURETIC PEPTIDE TYPE C; NITRIC OXIDE SYNTHASE; PHOSPHOTRANSFERASE; PLASMID DNA; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN SYNTHASE; SCATTER FACTOR; SUPEROXIDE DISMUTASE; THYMIDINE KINASE; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE PLASMINOGEN ACTIVATOR; TRANSCRIPTION FACTOR E2F; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VIRUS VECTOR;

ARTERY DISEASE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; MULTICENTER STUDY; RESTENOSIS; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ARTERIOSCLEROSIS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GRAFT OCCLUSION, VASCULAR; HUMANS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

ADENOVIRIDAE;

EID: 0036322887     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262110-00001     Document Type: Review

References (77)

1. Mechanisms and prevention of restenosis: From experimental models to clinical practice
2. A call for provisional stenting: The balloon is back!
3. Cardiovascular gene therapy
4. Transcriptional targeting of replication-defective adenovirus transgene expression to smooth muscle cells in vivo
5. Design of a muscle cell-specific expression vector utilising human vascular smooth muscle alpha-actin regulatory elements
6. Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display
7. Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor
8. Chimeric smooth muscle-specific enhancer/promoters: Valuable tools for adenovirus-mediated cardiovascular gene therapy
9. Gene therapy for restenosis
10. Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia
11. Catheter-mediated VEGF gene transfer to human lower limb arteries after PTA
12. Adenoviral vectors for gene transfer
13. Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods
14. Clinical applications of vascular gene therapy
15. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5
16. HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses
17. Vascular cell adhesion molecule-1 augments adenovirus-mediated gene transfer
18. Gene transfer into the carotid artery using an adventitial collar: Comparison of the effectiveness of the plasmid- liposome complexes, retroviruses, pseudotyped retroviruses, and adenoviruses
19. Baculovirus-mediated periadventitial gene transfer to rabbit carotid artery
20. Adeno-associated virus vectors for vascular gene delivery
21. Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors
22. Vegf gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries
23. Efficient adventitial gene delivery to rabbit carotid artery with cationic polymer-plasmid complexes
24. Antisense oligonucleotide inhibition of PDGFR-beta receptor subunit expression directs suppression of intimal thickening
25. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia
26. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty
27. Percutaneous adenoviral gene transfer into porcine coronary arteries: Is catheter-based gene delivery adapted to coronary circulation?
28. Local drug delivery: Current applications
29. Pathophysiology of restenosis: Interaction of thrombosis, hyperplasia, and/or remodeling
30. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty
31. Purification and properties of porcine platelet-derived growth factor
32. A human osteosarcoma cell line secretes a growth factor structurally related to a homodimer of PDGF A-chains
33. Two classes of PDGF receptor recognize different isoforms of PDGF
34. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor
35. Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor
36. PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor
37. PDGF-D, a new protease-activated growth factor
38. sis (platelet-derived growth factor B chain) gene transcript levels are elevated in human atherosclerotic lesions compared to normal artery
39. Platelet-derived growth factor gene expression in human atherosclerotic plaques and normal artery wall
40. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery
41. PDGFbeta receptor blockade inhibits intimal hyperplasia in the baboon
42. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF
43. Targeting endogenous platelet-derived growth factor B-chain by adenovirus-mediated gene transfer potently inhibits in vivo smooth muscle proliferation after arterial injury
44. Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo
45. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease
46. Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease
47. Molecular and biological properties of vascular endothelial growth factor
48. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery
49. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta
50. In vivo transfer of human hepatocyte growth factor gene accelerates re-endothelialization and inhibits neointimal formation after balloon injury in rat model
51. Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene
52. Adventitial gene transfer of recombinant endothelial nitric oxide synthase to rabbit carotid arteries alters vascular reactivity
53. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats
54. Apoptosis: Basic concepts and implications in coronary artery disease
55. Regulation of cellular proliferation and intimal formation following balloon injury in atherosclerotic rabbit arteries
56. Reduction of restenosis after angioplasty in an atheromatous rabbit model by suicide gene therapy
57. Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury
58. Gene therapy to promote thromboresistance: Local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model
59. Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit model
60. Arterial remodeling after coronary angioplasty: A serial intravascular ultrasound study
61. Histopathology of postpercutaneous transluminal coronary angioplasty remodeling in human coronary arteries
62. Remodeling and neointimal formation in the carotid artery of normal and P-selectin-deficient mice
63. Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow
64. Adenovirus-mediated human tissue kallikrein gene delivery inhibits neointima formation induced by interruption of blood flow in mice
65. Neointimal tissue response at sites of coronary stenting in humans: Macroscopic, histological, and immunohistochemical analyses
66. Pathology of acute and chronic coronary stenting in humans
67. Angiogenesis, vascular endothelial growth factor and platelet-derived growth factor-BB expression, iron deposition, and oxidation-specific epitopes in stented human coronary arteries
68. Fibrin-film stenting in a porcine coronary injury model: Efficacy and safety compared with uncoated stents
69. Genetically engineered endothelial cells remain adherent and viable after stent deployment and exposure to flow in vitro
70. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: One-year angiographic and intravascular ultrasound follow-up
71. Arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease
72. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial
73. Evaluation of angiogenesis and side effects in ishemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ
74. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension: Evidence for a maintenance role in quiescent adult endothelium
75. Vascular endothelial growth factor enhances atherosclerotic plaque progression
76. Effect of human recombinant vascular endothelial growth factor165 on progression of atherosclerotic plaque
77. Virus treatment questioned after gene therapy death